Understand the Association Between Peritoneal Dialysis Status and Gene Polymorphisms of VEGF and KDR

Gene Polymorphisms of VEGF and KDR Are Associated With Initial High Transport Status in Peritoneal Dialysis

Peritoneal dialysis (PD) is an effective and successful way of renal replacement therapy. The initial transport status is related to distribution of blood vessels and micro inflammation state in peritoneum before PD. Vascular endothelial growth factor(VEGF) and its receptor, kinase insert domain containing receptor(KDR) may play important roles on initial transport status.

This study include 200 PD patients from Renji Hospital in Shanghai, China. According to the 4h D/P Cr within three months of starting PD therapy, we analyzed the association between the polymorphisms of VEGF and KDR and initial peritoneal transport property.

Study Overview

• Status: Completed
• Conditions: Peritoneal Dialysis

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 310115
      • Renji Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Both gender, end stage renal disease on PD treatment

Description

Inclusion Criteria:

1. Patients are Han Chinese;
2. Patients prepare for dialysis in our center, and start PD within 3 months after abdominal catheterization;
3. Patients successfully complete the first peritoneal equilibration test(PET);
4. Follow up regularly in our PD center.

Exclusion Criteria:

1. Patients from hemodialysis to peritoneal dialysis;
2. Patients who need peritoneal dialysis due to transplant-renal loss;

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The relationship between VEGF and KDR Gene polymorphisms and initial transport status in peritoneal dialysis	According to the 4h dialysate over plasma ratio for creatinine （D/P Cr） within three months of starting PD therapy, patients were divided into high transport(H) or high average transport(HA) (H/HA) group and low transport(L) or low average transport(LA) (L/LA) group. Gene polymorphisms of selected VEGF and KDR SNPs were analyzed using extracted blood DNA from these patients. We aimed to investigate the relationship between VEGF and KDR gene polymorphisms and initial peritoneal transport property.	For each patient, the outcome would be cross sectional measured at the time the patient does first/initial Peritoneal Equilibration Test. The data collection time period of the study is within 3 months.

Collaborators and Investigators

• Sponsor: RenJi Hospital
• Investigators: Principal Investigator: YUE QIAN, MD, Renji Hospital

Publications and helpful links

General Publications

• Qian Y, Ding L, Cao L, Yu Z, Shao X, Wang L, Zhang M, Wang Q, Che X, Jiang N, Yan H, Fang W, Jin Y, Huang J, Gu A, Ni Z. Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis. BMC Nephrol. 2022 Nov 14;23(1):365. doi: 10.1186/s12882-022-02975-5.

Study record dates

Study Major Dates

• Study Start (Actual): May 10, 2018
• Primary Completion (Actual): October 30, 2020
• Study Completion (Actual): December 30, 2020

Study Registration Dates

• First Submitted: April 27, 2021
• First Submitted That Met QC Criteria: May 10, 2021
• First Posted (Actual): May 17, 2021

Study Record Updates

• Last Update Posted (Actual): May 17, 2021
• Last Update Submitted That Met QC Criteria: May 10, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 2018-220

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No